PEG-SN38 (EZN-2208)
- Phase I Trial of Polyethylene Glycol (PEG) Conjugated SN38 in Children with Recurrent or Refractory Neuroblastoma (NB) and Other Solid Tumors
- Final analysis of Phase 2 study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC) demonstrates activity in patients with triple negative breast cancer (TNBC) and in platinum pretreated patients
- Customized PEG Linkers Improve the Pharmaceutical Properties of Cytotoxic Small Molecules
- EZN-2208, a novel anticancer agent, in patients with advanced malignancies; a Phase 1 dose-escalation study
- Pharmacokinetics of EZN-2208, a novel anticancer agent, in patients with advanced malignancies
- Phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients with advanced malignancies
- A novel polyethyleneglycol-SN38 conjugate, EZN-2208, downregulates HIF-1a
- EZN-2208 A Novel PEGylated SN-38 Drug Conjugate
- PEG-SN38 CCR Article- Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model (Clinical Cancer Research)
- EZN-2208 Phase 2 MBC Poster SABCS — December 2011
- ENZ-2208 04 PEG-SN38 CRC Phase 2 ASCO GI 2012 Poster
HIF-1 alpha antagonist (EZN-2968)
- EZN-2968, a novel hypoxia-inducible factor-1a messenger ribonucleic acid antagonist
- Phase 1, pharmacokinetic, dose-escalation study of EZN-2968
- Down-modulation of messenger ribonucleic acid (mRNA) by EZN-2968, an hypoxia-inducible factor-1
- A RNA Antagonist of Hypoxia-Inducible Factor-1, EZN-2968, Inhibits Tumor Cell Growth (Molecular Cancer Therapeutics)
Survivin antagonist (EZN-3042)
- A novel locked nucleic acid oligonucleotide against survivin
- EZN-3042, a novel locked nucleic acid oligonucleotide specifically inhibits survivin expression
- Results of a Phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042
- Results of a Phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin messenger ribonucleic acid (mRNA) antagonist, administered with or without docetaxel in adult patients with advanced solid tumors or lymphoma
Androgen receptor mRNA antagonist (EZN-4176)
mRNA antagonists
- An antisense molecule to HER3 sustains growth inhibitory effects in gefitinib resistant cells
- Down regulation of B-catenin mRNA by a locked nucleic acid oligonucleotide antagonist
- EZN-3920, an ErbB3-locked nucleic acid-based RNA inhibitor
- EZN-3920, an LNA antisense oligonucleotide RNA antagonist, down modulates HER3 expression and PI3K
- In vitro and in vivo characterization of two novel B-catenin RNA antagonists
- Reduced expression of HER3 with a specific RNA antagonist is associated with antitumor effects
- Targeting HER3 mRNA by a locked nucleic antisense molecule
- Targeting the hedgehog pathway by LNA oligonucleotide based-GLI2 RNA antagonists
- The Antitumor Activity of EZN-4150
- EZN-3920, a HER3 antagonist, enhances the antitumor effect of gefitinib and lapatinib in xenograft models
- Targeting the b-catenin oncogene in multiple myeloma disease using locked nucleic acid antisense technology
- Marked sensitivity to mRNA targeting by LNA antisense in tumor cells without a delivery system: Lessons learned
Customized PEGylation Linker Technology
- Controlled Release of Proteins through Releasable PEGylation
- Customized PEG Linkers Improve Tumor Delivery of RNA Antagonist Oligonucleotides
- Novel customized releasable polyethylene glycol linkers improve tumor delivery
- Novel PEG-Nanoparticles Enhance Delivery of RNA Antagonist Against Oligonucleotide in Tumor Cells and in Mice
- Novel Releasable PEG-Conjugates of LNA Antisense Oligonucleotides as Potent mRNA Antagonists to Cancer Targets